Protocol Ledger

NCT05050162 · Phase II/III · ACTIVE NOT RECRUITING

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Interventional Phase II/III clinical trial protocol NCT05050162 sponsored by NRG Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-02-01 Enrollment: 475 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05050162
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)475 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05050162
Protocol FieldVerified Registry Value
NCT IdentifierNCT05050162
Consolidated Lead SponsorNRG Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment475 participants (ACTUAL)
Registered Start Date2022-02-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI